Lazard Asset Management
HRTX icon

Lazard Asset Management’s Heron Therapeutics HRTX Stock Holding History

Lazard Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,815
Closed -$30K – 2397
2025
Q1 		$30K Buy
+13,815
New +$26.8K ﹤0.01% 2077
2024
Q3 		– Sell
-98,182
Closed -$343K – 2346
2024
Q2 		$343K Buy
+98,182
New +$302K ﹤0.01% 1361
2020
Q4 		– Sell
-4,180
Closed -$61K – 1900
2020
Q3 		$61K Sell
4,180
-1,285
-24% -$20K ﹤0.01% 1124
2020
Q2 		$80K Buy
5,465
+1,762
+48% +$28.9K ﹤0.01% 1074
2020
Q1 		$43K Buy
+3,703
New +$69.6K ﹤0.01% 1231
2018
Q3 		– Sell
-36,520
Closed -$1.42M – 1079
2018
Q2 		$1.42M Buy
+36,520
New +$1.16M ﹤0.01% 698

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lazard Asset Management's HRTX Position: Q2 2025 in Review

Lazard Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2025, closing a stake of 13,815 shares — an estimated $30K sold.

Lazard Asset Management first reported a position in HRTX in Q2 2018 and held it in 6 quarters. The position peaked at $1.42M in Q2 2018. 171 funds tracked by Wall St. Rank hold HRTX as of Q2 2025.

  • Lazard Asset Management reported no remaining Heron Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 13,815 Heron Therapeutics shares in Q2 2025, an estimated $30K.
  • Lazard Asset Management first reported a position in Heron Therapeutics in Q2 2018 and held it in 6 quarters.
  • Lazard Asset Management's Heron Therapeutics position peaked at $1.42M in Q2 2018.
  • 171 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.